Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients

Cancer Science

Volumn 102, Issue 8, 2011, Pages 1590-1596

  Qian, Niansong ^a,b   Ueno, Takayuki ^a   Kawaguchi Sakita, Nobuko ^a   Kawashima, Masahiro ^a   Yoshida, Noriyuki ^a   Mikami, Yoshiki ^a   Wakasa, Tomoko ^c   Shintaku, Masayuki ^c   Tsuyuki, Shigeru ^c   Inamoto, Takashi ^d   Toi, Masakazu ^a  

^a KYOTO UNIVERSITY   (Japan)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c OSAKA RED CROSS HOSPITAL   (Japan)

^d TENRI HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CANCER SIZE; CLINICAL ARTICLE; CORRELATIONAL STUDY; DEATH; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; STROMA CELL; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CAVEOLIN 1; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS;

EID: 79960436389     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01985.x     Document Type: Article

References (45)

1. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer - current status and future directions. Ann Oncol 2010; 21: 7-12.
2. Yamashiro H, Toi M. Update of evidence in chemotherapy for breast cancer. Int J Clin Oncol 2008; 13: 3-7.
3. Shatz M, Liscovitch M. Caveolin-1: a tumor-promoting role in human cancer. Int J Radiat Biol 2008; 84: 177-89.
4. Cantiani L, Manara MC, Zucchini C et al. Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling. Cancer Res 2007; 67: 7675-85.
5. Wikman H, Kettunen E, Seppänen JK et al. Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene 2002; 21: 5804-13.
6. Kato K, Hida Y, Miyamoto M et al. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 2002; 94: 929-33.
7. Suzuoki M, Miyamoto M, Kato K et al. Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer 2002; 87: 1140-4.
8. Cohen AW, Hnasko R, Schubert W, Lisanti MP. Role of caveolae and caveolins in health and disease. Physiol Rev 2004; 84: 1341-79.
9. Zhang W, Razani B, Altschuler Y et al. Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1. J Biol Chem 2000; 275: 20717-25.
10. Park WY, Park JS, Cho KA et al. Up-regulation of caveolin attenuates epidermal growth factor signaling in senescent cells. J Biol Chem 2000; 275: 20847-52.
11. Sotgia F, Schubert W, Pestell RG, Lisanti MP. Genetic ablation of caveolin-1 in mammary epithelial cells increases milk production and hyper-activates STAT5a signaling. Cancer Biol Ther 2006; 5: 292-7.
12. Woodman SE, Ashton AW, Schubert W et al. Caveolin-1 knockout mice show an impaired angiogenic response to exogenous stimuli. Am J Pathol 2003; 162: 2059-68.
13. Volonte D, Zhang K, Lisanti MP, Galbiati F. Expression of caveolin-1 induces premature cellular senescence in primary cultures of murine fibroblasts. Mol Biol Cell 2002; 13: 2502-17.
14. Chretien A, Piront N, Delaive E, Demazy C, Ninane N, Toussaint O. Increased abundance of cytoplasmic and nuclear caveolin 1 in human diploid fibroblasts in H(2)O(2)-induced premature senescence and interplay with p38alpha(MAPK). FEBS Lett 2008; 582: 1685-92.
15. Ostman A, Augsten M. Cancer-associated fibroblasts and tumor growth - bystanders turning into key players. Curr Opin Genet Dev 2009; 19: 67-73.
16. Qian N, Ueno T. Is dysfunction of caveolin-1 a link between systemic sclerosis and breast cancer, opening a window on both etiologies? Arch Med Res 2010; 41: 297-301.
17. Williams TM, Sotgia F, Lee H et al. Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells. Am J Pathol 2006; 169: 1784-801.
18. Witkiewicz AK, Dasgupta A, Sotgia F et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 2009; 174: 2023-34.
19. Witkiewicz AK, Dasgupta A, Nguyen KH et al. Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biol Ther 2009; 8: 1071-9.
20. Sakamoto G, Inaji H, Akiyama F et al; Japanese Breast Cancer Society. General rules for clinical and pathological recording of breast cancer 2005. Breast Cancer 2005; 12(Suppl): S1-27.
21. Liu P, Rudick M, Anderson RG. Multiple functions of caveolin-1. J Biol Chem 2002; 277: 41295-8.
22. Perrone G, Altomare V, Zagami M et al. Caveolin-1 expression in human breast lobular cancer progression. Mod Pathol 2009; 22: 71-8.
23. Sloan EK, Ciocca DR, Pouliot N et al. Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol 2009; 174: 2035-43.
24. Liedtke C, Kersting C, Bürger H, Kiesel L, Wülfing P. Caveolin-1 expression in benign and malignant lesions of the breast. World J Surg Oncol 2007; 5: 110.
25. Rønnov-Jessen L, Bissell MJ. Breast cancer by proxy: can the microenvironment be both the cause and consequence? Trends Mol Med 2009; 15: 5-13.
26. Mercier I, Casimiro MC, Wang C et al. Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: implications for the response to hormonal therapy. Cancer Biol Ther 2008; 7: 1212-25.
27. Savage K, Lambros MB, Robertson D et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 2007; 13: 90-101.
28. Sagara Y, Mimori K, Yoshinaga K et al. Clinical significance of Caveolin-1, Caveolin-2 and HER2/neu mRNA expression in human breast cancer. Br J Cancer 2004; 91: 959-65.
29. Park SS, Kim JE, Kim YA et al. Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast. Histopathology 2005; 47: 625-30.
30. Couet J, Sargiacomo M, Lisanti MP. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem 1997; 272: 30429-38.
31. Kim YN, Wiepz GJ, Guadarrama AG, Bertics PJ. Epidermal growth factor-stimulated tyrosine phosphorylation of caveolin-1. Enhanced caveolin-1 tyrosine phosphorylation following aberrant epidermal growth factor receptor status. J Biol Chem 2000; 275: 7481-91.
32. Decensi A, Guerrieri-Gonzaga A, Gandini S et al. Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol 2011; 22: 582-7.
33. Sotgia F, Rui H, Bonuccelli G, Mercier I, Pestell RG, Lisanti MP. Caveolin-1, mammary stem cells, and estrogen-dependent breast cancers. Cancer Res 2006; 66: 10647-51.
34. Fiucci G, Ravid D, Reich R, Liscovitch M. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 2002; 21: 2365-75.
35. Ravid D, Maor S, Werner H, Liscovitch M. Caveolin-1 inhibits anoikis and promotes survival signaling in cancer cells. Adv Enzyme Regul 2006; 46: 163-75.
36. Lavie Y, Fiucci G, Liscovitch M. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J Biol Chem 1998; 273: 32380-3.
37. Lavie Y, Liscovitch M. Changes in lipid and protein constituents of rafts and caveolae in multidrug resistant cancer cells and their functional consequences. Glycoconj J 2000; 17: 253-9.
38. Quest AF, Gutierrez-Pajares JL, Torres VA. Caveolin-1: an ambiguous partner in cell signaling and cancer. J Cell Mol Med 2008; 12: 1130-50.
39. Sotgia F, Williams TM, Schubert W et al. Caveolin-1 deficiency (-/-) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness. Am J Pathol 2006; 168: 292-309.
40. Yang G, Timme TL, Naruishi K et al. Mice with cav-1 gene disruption have benign stromal lesions and compromised epithelial differentiation. Exp Mol Pathol 2008; 84: 131-40.
41. Pavlides S, Tsirigos A, Vera I et al. Transcriptional evidence for the "Reverse Warburg Effect" in human breast cancer tumor stroma and metastasis: similarities with oxidative stress, inflammation, Alzheimer's disease, and "Neuron-Glia Metabolic Coupling". Aging (Albany NY) 2010; 2: 185-99.
42. Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D et al. Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle 2010; 9: 2423-33.
43. Pavlides S, Tsirigos A, Vera I et al. Loss of stromal caveolin-1 leads to oxidative stress, mimics hypoxia and drives inflammation in the tumor microenvironment, conferring the "reverse Warburg effect": a transcriptional informatics analysis with validation. Cell Cycle 2010; 9: 2201-19.
44. Martinez-Outschoorn UE, Trimmer C, Lin Z et al. Autophagy in cancer associated fibroblasts promotes tumor cell survival: role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment. Cell Cycle 2010; 9: 3515-33.
45. Bonuccelli G, Whitaker-Menezes D, Castello-Cros R et al. The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. Cell Cycle 2010; 9: 1960-71.